CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia

Over the past decades, survival of patients with acute lymphoblastic leukemia (ALL) has dramatically improved, but the subgroup of patients with relapsed/refractory ALL still continues to have dismal prognosis. As an emerging therapeutic approach, chimeric antigen receptor-modified T-cells (CAR-T) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Vairy, Stephanie, Garcia, Julia Lopes, Teira, Pierre, Bittencourt, Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237143/
https://www.ncbi.nlm.nih.gov/pubmed/30518999
http://dx.doi.org/10.2147/DDDT.S138765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237143/
https://www.ncbi.nlm.nih.gov/pubmed/30518999
http://dx.doi.org/10.2147/DDDT.S138765

Ejemplares similares